Clinical trials: High-sensitivity C-reactive Protein
Arthritis, Rheumatoid
SB-681323 In Subjects With Rheumatoid Arthritis
The purpose of this research is to find out how effective and safe SB-681323 will be in the treatment of RA when it is added to standard anti-rheumatic treatments.
- Trial name
- NCT00320450
- Testing
- SB-681323
- Where
- 41 sites in Denmark, Germany and 7 more
- Volunteers
- 78 people
- Sponsor
- GlaxoSmithKline
Healthy
Study to Evaluate the Effect of Botanical Dietary Supplements on Inflammation in Healthy People
The purpose of the study is to evaluate the effect of botanical dietary supplements on inflammation in healthy people with different genetic responses to inflammation.
- Trial name
- NCT00303238
- Testing
- Rose hips extract + blueberry/blackberry extract + resveravine, Rose hips extract + blueberry/blackberry extract + Aframomum melegueta extract, Rose hips extract + resveravine + Aframomum melegueta extract
- Where
- 8 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Access Business Group
Healthy
A Study to Evaluate the Effect of Astaxanthin in Healthy Participants
Astaxanthin is recognized as a bioactive compound with potential benefits for human health. This study aims to evaluate a specific nutritional supplement impact on markers of oxidative stress, inflammation, lipid levels, blood…
- Trial name
- NCT05376501
- Testing
- Astaxanthin
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- LycoRed Ltd.
Crohn's Disease
A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease
The purpose of this trial is to evaluate natalizumab in individuals with moderately to severely active Crohn's Disease.
- Trial name
- NCT00078611
- Testing
- natalizumab
- Where
- 75 sites in United States, Canada
- Volunteers
- 462 people
- Sponsor
- Biogen
Diabetes Mellitus, Type 2
Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors
This study was conducted to demonstrate superiority of nateglinide in postprandial glucose fluctuation, dyslipidemia, and inflammatory status improvement.
- Trial name
- ENERGY (NCT00928889)
- Testing
- Nateglinide 120 mg, Acarbose 50 mg
- Where
- 6 sites in China
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Respiratory Tract Infections, Urinary Tract Infections
HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study
This study will analyze gene expression data (HostDx Sepsis test) from blood samples collected from participants with suspected infections.
- Conditions
- Respiratory Tract Infections, Urinary Tract Infections, Skin and Soft Tissue Infections, Intraabdominal Infections
- Trial name
- NCT03744741
- Testing
- HostDx Sepsis
- Where
- 7 sites in United States, Greece
- Volunteers
- 585 people
- Sponsor
- Inflammatix
Obesity, Elevated High-sensitivity C-reactive Protein (hsCRP)
A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity
This study is being done to look at the efficacy single and multiple ascending dose study investigating safety, tolerability, pharmacokinetics, food effect and target engagement in healthy adults including a single cohort in…
- Trial name
- NCT07693868
- Testing
- NNC6022-0004
- Where
- Netherlands
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
End Stage Kidney Disease (ESKD)
A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)
This is a phase 1b, partial-blind (Sponsor unblinded), randomized, multicenter, placebo-controlled study. The primary objective of this study is to evaluate the pharmacokinetics (PK) of CSL300 after single and multiple doses in…
- Trial name
- NCT07619820
- Testing
- CSL300
- Where
- China
- Volunteers
- 24 people
- Sponsor
- CSL Behring
Crohn's Disease
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
This study will evaluate the efficacy and safety of adalimumab induction and maintenance treatment in subjects with moderately to severely active Crohn's disease in China.
- Trial name
- NCT02499783
- Testing
- adalimumab
- Volunteers
- 205 people
- Sponsor
- AbbVie
Atherosclerosis
Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease
This study is a, randomized, double-blind, placebo-controlled phase 2a trial evaluating the potential of MLN1202 to reduce circulating levels of C-reactive protein (CRP)in patients with risk factors for Atherosclerotic…
- Trial name
- NCT00715169
- Testing
- MLN1202
- Volunteers
- 108 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Juvenile Idiopathic Arthritis
Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis
The primary objective of this study is to evaluate the pharmacokinetics (PK) of olokizumab (OKZ) in patients with polyarticular juvenile idiopathic arthritis aged >2 and <18 years in two doses (64 mg or 48 mg every 4 weeks)…
- Trial name
- NCT07517575
- Testing
- OKZ q4w
- Where
- 14 sites in Russia
- Volunteers
- 71 people
- Sponsor
- R-Pharm International, LLC
Metabolic Syndrome, Hyperlipidemia
The Effects of ProAlgaZyme on HDL Cholesterol in Individuals With Metabolic Syndrome
The purpose of this study is to determine the effectiveness of ProAlgaZyme in increasing levels of HDL 'good' cholesterol and decreasing total cholesterol and C-reactive protein in patients with Metabolic Syndrome.
- Trial name
- NCT00518960
- Testing
- ProAlgaZyme
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Health Enhancement Products, Inc.
Stroke, Ischemic
CASTRO1 - Study on CRP Apheresis After Ischemic Stroke
CASTRO1 is a study to investigate the reduction of C-reactive protein (CRP) by therapeutic apheresis (CRP-apheresis) in patients after primary treatment of ischemic stroke.
- Trial name
- CASTRO1 (NCT04417231)
- Testing
- CRP apheresis
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- Pentracor GmbH
Post-cardiac Surgery
Study on CRP Apheresis After Coronary Bypass Surgery
The CABY1 study is conducted open, controlled, randomized and monocentric. The efficacy and tolerability of CRP apheresis in patients undergoing elective primary coronary bypass surgery is investigated.
- Trial name
- CABY1 (NCT04745468)
- Testing
- CRP apheresis
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Pentracor GmbH
Rheumatoid Arthritis
Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis
The purpose of this study was to determine the efficacy, dose response, and safety of M52951 in participants with Rheumatoid Arthritis (RA), and to consider a dose to took forward into Phase III development.
- Trial name
- NCT03233230
- Testing
- M2591 25 mg QD, M2951 75 mg QD, M2951 50 mg BID
- Where
- 97 sites in United States, Argentina and 10 more
- Volunteers
- 390 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Anorexia, Cancer Cachexia
Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia
The purpose of this study is to determine whether patients with advanced cancers who receive OHR/AVR118 solution for injection into the skin can achieve improvement in quality of life.
- Trial name
- NCT01206335
- Testing
- OHR/AVR118
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Ohr Pharmaceutical Inc.
Healthy Volunteers, C-Reactive Protein
A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)
The main purpose of this study is to evaluate the safety and tolerability of LY5625575 in healthy participants (including Japanese and Chinese) and in participants with high levels of a marker for inflammation (C-reactive…
- Trial name
- NCT07801300
- Testing
- LY5625575
- Where
- 2 sites in United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Determination of Normal Reference Values of CRP, Procalcitonin, and Lactate Levels for the Nanōmix eLab® System
The main objective of this clinical study is to determine the normal reference range of the Nanōmix eLab® (eLab) C-Reactive Protein, Procalcitonin and Lactate Assay.
- Trial name
- NCT03619109
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Nanomix
Acute Respiratory Tract Infections
FebriDx DISRUPT Acute Respiratory Infection Trial in Acute Respiratory Infection: An Evaluation of FebriDx® POC Test
The aim of this study is to determine performance characteristics of the FebriDx test in predicting viral or bacterial infection etiology among febrile (observed or reported) patients presenting the emergency department, urgent…
- Trial name
- NCT02018198
- Testing
- FebriDx
- Where
- 20 sites in United States
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Rapid Pathogen Screening
Hypertension
Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)
The study compares the efficacy of an aggressive versus a moderate initial antihypertensive regimen to reduce blood pressure in patients with Stage 2 hypertension.
- Trial name
- NCT00154271
- Testing
- Valsartan, Valsartan HCT
- Volunteers
- 1,677 people
- Sponsor
- Novartis